Clene Stock Jumps After FDA Opens Door to Fast-Track ALS Drug Filing
Clene Inc. is moving to pursue faster U.S. approval for its ALS drug candidate, CNM-Au8. The company cited FDA meeting minutes indicating its current data could support a New Drug Application—the key step toward seeking FDA clearance for a new therapy.